Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Multiparameter Immunochromatographic Assay Detects and Differentiates Hepatitis C Antibodies

By LabMedica International staff writers
Posted on 14 Aug 2013
A hepatitis C (HCV) rapid test has been developed that should provide additional information about the infection profile.

The Multisure HCV antibody assay is a qualitative, multiparameter, immunochromatographic assay, intended for the detection and differentiation of Hepatitis C antibodies that may be present in patients with acute or chronic Hepatitis C infection. More...
The test was developed based on the patented reverse-flow technology, giving greater sensitivity and stronger visual signals.

Developed by MP Diagnostic (Solon, OH, USA), the Multisure HCV antibody assay uses human whole blood, plasma, or serum. It has a short test-time and can detect and differentiate HCV antibodies against both structural and non-structural proteins across all six genotypes. The assay is instrument free, easy to use, and is suitable for use at Point-of-Care (POC) or with automation. It does not require highly trained personnel to perform the test. It has shown excellent correlation with polymerase chain reaction (PCR), enzyme immunoassay (EIA), and Immunoblot.

MP Biomedicals received the CE marking for its new, multiparameter Hepatitis C test.

Related Links:

MP Diagnostic



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.